Ignite Creation Date:
2024-10-25 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06506422
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-11
Brief Title:
Empagliflozin Reversal of Arterial StiffnEss in Aging
Sponsor:
None
Organization:
None
Study Overview
Official Title:
SGLT2 Inhibition as a Therapeutic Strategy to Reverse Arterial Stiffening in Aging
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ERASE-Aging
Brief Summary:
Randomized placebo-controlled clinical trial in a cohort of males n40 and females n40 60-80 years of age with the hypothesis that SGLT2 inhibition with empagliflozin 10mgday for 12 weeks reduces aging-related arterial stiffening
Detailed Description:
The investigators will employ a double-blinded randomized placebo control trial to determine the effects of 12 weeks of sodium glucose co-transporter 2 SGLT2 inhibition with empagliflozin 10 mg daily or matching placebo Empagliflozin has been shown to decrease cardiovascular events and arterial stiffness in different populations Placebo will be included for comparison purposes as empagliflozin is not a standard therapy for aging-associated arterial stiffness
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None